Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
- Conditions
- AsthmaGastroesophageal Reflux Disease
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- Associated Scientists to Help Minimize Allergies
- Target Recruit Count
- 80
- Registration Number
- NCT00214552
- Locations
- 🇺🇸
ASTHMA, Inc., Seattle, Washington, United States
Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)
- Conditions
- Esophageal Reflux
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-05-08
- Lead Sponsor
- University of Kansas
- Target Recruit Count
- 24
- Registration Number
- NCT00222170
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Rabeprazole Protection of Aspirin Induced Gastric Damage.
- Conditions
- Normal Subjects
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-01-11
- Lead Sponsor
- Temple University
- Target Recruit Count
- 30
- Registration Number
- NCT00220857
- Locations
- 🇺🇸
Temple University School of Medicine, Philadelphia, Pennsylvania, United States
Post-nasal Drainage as an Extraesophageal Manifestation of Reflux
- Conditions
- Postnasal Drainage
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 50
- Registration Number
- NCT00199953
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2008-01-16
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 24
- Registration Number
- NCT00204698
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
- Conditions
- Non-erosive Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-10-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00165672
A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
- Conditions
- Non-erosive Gastroesophageal Reflux Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-07-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 288
- Registration Number
- NCT00165646
Maintenance Intermittent Therapy for Symptomatic GERD Patients
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00165841
- Locations
- 🇺🇸
Quality Care Medical Center Inc., Vista, California, United States
The Role of CYP2C19 on the Eradication of H. Pylori Infection:Implication of PK/PD Relationships
- Conditions
- Peptic Ulcer With H. Pylori InfectionGastritis With H. Pylori Infection
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2005-11-23
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT00162877
- Locations
- 🇨🇳
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2009-12-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT00132496
- Locations
- 🇺🇸
Marshall University, Huntington, West Virginia, United States
🇺🇸Professional Clinical Research, Cadillac, Michigan, United States
🇺🇸University of Pediatrics, Mason, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.